Introducing a novel plasmonics-enhanced lateral flow immunoassay (LFIA) for rapid micronutrient screening at point-of-care and home settings. This platform boasts up to 1000x sensitivity improvement using bimetallic nanostructures for multiplexed, unprocessed sample analysis.
The proposed advanced colorimetric lateral flow immunoassay (LFIA) represents a significant leap in micronutrient detection technologies. By leveraging a novel amplification-free capture mechanism and a plasmonics-enhanced colorimetric detection system, this platform is designed for rapid screening in both point-of-care (POCT) and home care testing (HCT) environments. The system's standout feature is its use of hybrid bimetallic nanostructures, specifically silver-coated gold nanostars, which significantly boost sensitivity and specificity. This technology supports multiplexed detection directly from complex, unprocessed biological samples, offering a modular and user-friendly architecture adaptable to various diagnostic formats.
Currently at Technology Readiness Level 2, this innovation has been validated conceptually through design and synthesis of the bimetallic gold nanostars. Further development is focused on optimizing nanoparticle morphology and integrating multifunctional sensing capabilities for practical applications.
Duke University is a mid-sized, comprehensive private research university in Durham, North Carolina, anchored by a globally recognized academic medical center. Co-located campus and clinical facilities enable rapid bench-to-bedside translation, and shared core laboratories are accessible to external partners. Proximity to Research Triangle Park links Duke to a dense network of R&D-intensive companies, supported by centralized corporate engagement for sponsored research and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD. A dedicated technology transfer office supports IP strategy, licensing, startups, and industry collaboration.